Simplification of Excipient Solution for Implanting Candidate Human H9-scNSC Cell Line for Spinal Cord Injury
Grant Award Details
Grant Number:
DISC2P-12212
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$180,000
Status:
Closed
Progress Reports
Reporting Period:
Year 1
Grant Application Details
Application Title:
Simplification of Excipient Solution for Implanting Candidate Human H9-scNSC Cell Line for Spinal Cord Injury
Public Abstract:
Research Objective
The objective of the proposed studies is to determine which of our excipient components are necessary for survival and neuronal differentiation of our clinical cell candidate therapy for SCI.
Impact
Identification of essential excipient components will greatly accelerate FDA approval and potential clinical application.
Major Proposed Activities
["Identify which components of the excipient are required for optimized survival and neuronal differentiation of H9-NSCsc graft into sites of spinal cord injury. "]
The objective of the proposed studies is to determine which of our excipient components are necessary for survival and neuronal differentiation of our clinical cell candidate therapy for SCI.
Impact
Identification of essential excipient components will greatly accelerate FDA approval and potential clinical application.
Major Proposed Activities
["Identify which components of the excipient are required for optimized survival and neuronal differentiation of H9-NSCsc graft into sites of spinal cord injury. "]
Statement of Benefit to California:
Spinal cord injury (SCI) affects approximately 1.2 million people in the U.S. with more than 11,000 new cases per year. This research plan will examine a novel therapeutic strategy for SCI. Neural stem cells will be generated from GMP-compatible human embryonic stem cells and grafted into animal models of SCI. We predict functional neuronal relays will form across a SCI lesion site that will mediate behavioral recovery.